Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
Elicio Therapeutics, Inc. Logo
Develops lymph node-targeted immunotherapies for aggressive, KRAS-driven cancers.
United States of America
ELTX
E-Novia Logo
A deep-tech factory building Physical AI ventures for mobility, logistics, and automation.
Italy
E9IA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Enveric Biosciences, Inc. Logo
Develops novel neuroplastogen drugs for severe mental health and addiction disorders.
United States of America
ENVB
Eone Diagnomics Genome Center Co., Ltd. Logo
Provides NGS-based genetic analysis for disease prevention and personalized healthcare.
South Korea
245620
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Eurofins-Cerep Logo
CRO offering preclinical drug profiling, screening & pharmacology testing for pharma/biotech.
France
ALECR
Evaxion A/S Logo
Develops AI-powered, personalized vaccines for cancer and infectious diseases.
United States of America
EVAX

Talk to a Data Expert

Have a question? We'll get back to you promptly.